Skip to main content

Niket Rele represents established and emerging companies in various sectors and industries across the full range of domestic and cross-border business combinations, outsourcing arrangements and related ventures. He is particularly recognized for his experience in mergers and acquisitions, cross border India-U.S. transactions, private equity transactions, corporate finance, strategic alliances and joint ventures, technology, pharmaceutical and biotech licensing transactions, and general corporate counseling. In the area of complex global outsourcing transactions, Mr. Rele regularly represents service providers and customers in structuring and negotiating sole-sourced and competitively bid, business-process outsourcing and information technology outsourcing arrangements, software licensing and support agreements, and technology transfers.

Mr. Rele, who is also qualified to practice law in India, regularly advises domestic and international companies on inbound and outbound business transactions in that sovereign state, representing Indian public and private companies in their US acquisitions, strategic alliances and joint ventures, as well as US and other international corporations in their entry strategies, investments and acquisitions in India.


  • Rising Pharmaceuticals and Casper Pharma in their joint sale to HIG Capital.
  • Advanced Technology Consulting Service Inc. in its sale to Nagarro Inc.
  • Tech Mahindra (NSE: TECHM) in its acquisition of DigitalOnUs.
  • Rising Pharma Holdings Inc. in its stalking horse bid and purchase of the assets of a generic pharmaceuticals business in a bankruptcy sale under Section 363 of the Bankruptcy Code.
  • eClerx Services Limited (BSE: 532927 | NSE: ECLERX) in its acquisition of Personiv.
  • True North Managers (f/k/a India Value Fund Advisors) and Zodius Capital in the sale of their portfolio company, Born Group, to Tech Mahindra.
  • Citron Pharma LLC, a pharmaceutical company focused on developing and marketing generic pharmaceutical products based in the United States, on all aspects of its $412 million sale of generic drug products and related assets to ACETO Corporation (NASDAQ: ACET).


Acritas Stars
Stand-Out Lawyer (2020)



  • LL.M., American University, 1995
  • LL.B., Bombay University, 1992
  • Bombay University, 1989


  • New York
  • India


  • Hindi
  • Marathi